Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly one apoB molecule carried on each particle of low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein, chylomicron remnants and lipoprotein(a). Because of this one-to-one relationship, a blood apoB concentration directly counts the total number of cholesterol-carrying, plaque-forming particles in the circulation, whereas an LDL-cholesterol value estimates only the cholesterol mass those particles carry. An apoB test therefore reports particle number rather than cholesterol content, and the two can diverge ("discordance") in people with diabetes, obesity, high triglycerides or metabolic syndrome.
Large Mendelian randomization studies, prospective cohorts and meta-analyses — in one pooling of 233,455 people apoB was the strongest lipid risk marker, about 12% better than LDL-cholesterol — indicate that apoB is the predominant lipid trait driving atherosclerotic cardiovascular disease, and that the particle number captured by apoB predicts myocardial infarction and residual risk more accurately than LDL-cholesterol or non-HDL-cholesterol, especially in statin-treated and discordant patients. In 2019 the European Society of Cardiology/European Atherosclerosis Society judged apoB a more accurate risk marker than LDL-C, and a 2024 National Lipid Association expert consensus recommends measuring it to refine risk, particularly with diabetes, obesity or high triglycerides. The evidence is not uniform: some cohorts (e.g., in women) found non-HDL-cholesterol as good as apoB, remnant cholesterol can add risk beyond apoB, and in established coronary disease and the general population very low apoB tracks with higher mortality through reverse causation (malnutrition, illness), producing U-shaped or "paradoxical" associations. Guidelines still treat LDL-C as the primary target and do not yet recommend routine apoB screening for everyone, and apoB is a risk marker rather than a treatment. This evidence concerns apolipoprotein B as a biomarker and the biology of atherogenic particles, not any specific commercial home test kit.
Peer-reviewed studies on the active compound — citations link to PubMed.
“apoB is a more accurate marker of all-cause mortality risk than LDL cholesterol”
“the total number of apoB particles determines cardiovascular risk”
“non-HDL-cholesterol and apoB are superior to LDL-cholesterol in predicting cardiovascular risk”
“However, when assessed together, only apoB was associated (adjusted hazard ratio [aHR] per 1 SD, 1.27; 95% CI, 1.15-1.40; P < .001). Similarly, only apoB was associated with MI in the secondary prevention cohort.”
“In multivariable MR, only apolipoprotein B (OR 1.92; 95% CI: 1.31-2.81; P < 0.001) retained a robust effect, with the estimate for LDL cholesterol (OR 0.85; 95% CI: 0.57-1.27; P = 0.44) reversing and that of triglycerides (OR 1.12; 95% CI: 1.02-1.23; P = 0.01) becoming weaker.”
“None of the residuals of LDL-C, non-HDL-C, or of log triglycerides remained significant when apoB was included in the model.”
Research describes the active mechanism and is not a claim about this specific product.
Across large prospective cohorts and meta-analyses, lower grip strength is consistently…
Across large studies, dysregulated cortisol patterns track with worse health: a…
Large prospective cohorts and meta-analyses consistently link higher serum GGT, even…
Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature…
Yes — its active compound is linked to 18 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.